Postprandial VLDL-TG metabolism in type 2 diabetes

Metabolism. 2017 Oct:75:25-35. doi: 10.1016/j.metabol.2017.07.002. Epub 2017 Jul 19.

Abstract

Background: Type 2 diabetes is associated with excess postprandial lipemia due to accumulation of chylomicrons and VLDL particles. This is a risk factor for development of cardiovascular disease. However, whether the excess lipemia is associated with an impaired suppression of VLDL-TG secretion and/or reduced clearance into adipose tissue is unknown.

Objective: We measured the postprandial VLDL-TG secretion, clearance and adipose tissue storage to test the hypothesis that impaired postprandial suppression of VLDL-TG secretion, combined with impaired VLDL-TG storage in adipose tissue, is associated with excess postprandial lipemia.

Design: We studied 11 men with type 2 diabetes and 10 weight-matched non-diabetic men using ex-vivo labeled VLDL-TG tracers during an oral high-fat mixed-meal tolerance test to measure postprandial VLDL-TG secretion, clearance and storage. In addition, adipose tissue biopsies were analyzed for LPL activity and cellular storage factors.

Results: Men with type 2 diabetes had greater postprandial VLDL-TG concentration compared to non-diabetic men. However, postprandial VLDL-TG secretion rate was similar in the two groups with equal suppression of VLDL-TG secretion rate (≈50%) and clearance rate. In addition, postprandial VLDL-TG storage was similar in the two groups in both upper body and lower body subcutaneous adipose tissue.

Conclusions: Despite greater postprandial VLDL-TG concentration, men with type 2 diabetes have similar postprandial suppression of VLDL-TG secretion and a similar ability to store VLDL-TG in adipose tissue compared to non-diabetic men. This may indicate that abnormalities in postprandial VLDL-TG metabolism are a consequence of obesity/insulin resistance more than a result of type 2 diabetes per se.

Trial registration: ClinicalTrials.gov NCT01961024.

Keywords: Lipid metabolism; Postprandial period; Triglyceride; Type 2 diabetes; VLDL.

MeSH terms

  • Adipose Tissue / metabolism
  • Adult
  • Aged
  • Body Composition
  • Diabetes Mellitus, Type 2 / metabolism
  • Humans
  • Hyperlipidemias
  • Insulin Resistance
  • Isotope Labeling
  • Lipoproteins, VLDL / metabolism*
  • Lipoproteins, VLDL / pharmacokinetics
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Obesity / metabolism
  • Postprandial Period*
  • Triglycerides / metabolism*
  • Triglycerides / pharmacokinetics

Substances

  • Lipoproteins, VLDL
  • Triglycerides
  • very low density lipoprotein triglyceride

Associated data

  • ClinicalTrials.gov/NCT01961024